Brochure More information from http://www.researchandmarkets.com/reports/2629674/ MediPoint: Total Hip Replacement - US Analysis and Market Forecasts Description: MediPoint: Total Hip Replacement - US Analysis and Market Forecasts Summary Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR). Our analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share. The mature market in the design of hip replacement products has led to a shift in the focus of developing orthopedic implants. Orthopedic surgery in the hip has become more minimally invasive unlike that of the past, with smaller incision sizes, the development of computer-navigated arthroplasty systems and even bone-preserving techniques such as resurfacing. This report addresses the various unmet needs, presents the current technology and the drivers for the future and market growth in the US. Adoption rates are examined, as well as the decision-makers, in order capture market share. Scope - An overview of arthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized US THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018. - Investigation of current and future market competition for THR - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon Reasons to buy - Understand the trends shaping and driving the US THR Market. - Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US THR market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market s device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. - What s the next big thing in US THR market landscape? Identify, understand and capitalize. Contents: 1 1 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 3 Disease Overview 3.1 Anatomy and Physiology 3.2 Pathophysiology 3.2.1 Overview 3.2.2 Osteoarthritis 3.2.3 Rheumatoid Arthritis 3.2.4 Post-traumatic Arthritis 3.2.5 Osteonecrosis 3.2.6 Injury 3.2.7 Bone Tumors 3.2.8 Other Diseases 3.3 Clinical Presentation 3.4 Clinical Outcomes 3.4.1 Overview 3.4.2 Conservative Therapy 3.4.3 Hip Arthroscopy 3.4.4 Hip Arthrodesis 3.4.5 Hemiarthroplasty (Partial) 3.4.6 Core Decompression 3.4.7 Hip Osteotomy 3.4.8 Resection Arthroplasty 3.4.9 Primary Total Hip Replacement 3.4.10 Revision Total Hip Replacement 3.4.11 Resurfacing Arthroplasty 3.4.12 Computer-Navigated Hip Replacement 3.5 Surgical Approaches 3.5.1 Anterolateral Approach 3.5.2 Posterior Approach 3.5.3 Direct Anterior Approach 3.5.4 Minimally Invasive Approaches 3.6 Epidemiology 3.6.1 US 3.7 Economic Impact 3.7.1 US 4 Competitive Assessment 4.1 Overview of Historical Designs 4.2 Marketed Products 4.2.1 Global Market Share 4.2.2 Primary Total Hip Replacement 4.2.3 Product Profiles by Company 5 Unmet Needs 5.1 Long-Term Clinical Data
5.2 Need for Continued Materials Research 5.3 Bearings 5.4 Refocus of Pipeline Products 5.5 Renewal of Resurfacing 5.6 Addressing the Learning Curve for Tier II Surgeons 5.7 Need for Cost Containment 5.8 Centralization 5.9 National Joint Registry 6 Pipeline Products 6.1 Overview 6.2 Primary Total Hip Pipeline Products 6.2.1 Exactech LPI Prime Hip System 6.2.2 EnduRo Bone-preserving Hip Stem 6.2.3 Deltamotion Acetabular Cup System 6.2.4 NovoSource Hip Implant 7 Industry Overview 7.1 Procedure Volumes 7.1.1 US 7.2 Market Access 7.2.1 US 7.3 Reimbursement Trends 7.3.1 US 7.4 Regulatory Issues/Recalls 7.4.1 DePuy Hip Replacement Recall 7.4.2 Stryker Hip Replacement Recall 7.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 7.4.4 Zimmer Durom Acetabular Component 7.4.5 Biomet Hip Replacement Complications 7.4.6 Wright Medical Conserve Hip Implant 7.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 7.5 Mergers & Acquisitions / Key Partnerships 7.5.1 Medtronic Acquires China Kanghui Holdings 7.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 7.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 7.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 7.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 7.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 8 Company Profiles 8.1 B. Braun 8.1.1 Overview 8.1.2 Portfolio Assessment 8.1.3 SWOT Analysis 8.2 Biomet Orthopedics 8.2.1 Overview 8.2.2 Portfolio Assessment 8.2.3 SWOT Analysis 8.3 Corentec Co. Ltd. 8.3.1 Overview 8.3.2 Portfolio Assessment 8.3.3 SWOT Analysis 8.4 Corin 8.4.1 Overview 8.4.2 Portfolio Assessment 8.4.3 SWOT Analysis 8.5 DePuy Synthes International 8.5.1 Overview 8.5.2 Portfolio Assessment 8.5.3 SWOT Analysis 8.6 Exactech 8.6.1 Overview 8.6.2 Portfolio Assessment 8.6.3 SWOT Analysis 8.7 Iconacy Orthopedic Implants LLC
8.7.1 Overview 8.7.2 Portfolio Assessment 8.7.3 SWOT Analysis 8.8 Implantcast GMBH 8.8.1 Overview 8.8.2 Portfolio Assessment 8.8.3 SWOT Analysis 8.9 JRI Orthopaedics 8.9.1 Overview 8.9.2 Portfolio Assessment 8.9.3 SWOT Analysis 8.10 Kyocera 8.10.1 Overview 8.10.2 Portfolio Assessment 8.10.3 SWOT Analysis 8.11 Limacorporate S.P.A 8.11.1 Overview 8.11.2 Portfolio Assessment 8.11.3 SWOT Analysis 8.12 Medacta 8.12.1 Overview 8.12.2 Portfolio Assessment 8.12.3 SWOT Analysis 8.13 Medtronic 8.13.1 Overview 8.13.2 Portfolio Assessment 8.13.3 SWOT Analysis 8.14 NovoSource Inc. 8.14.1 Overview 8.14.2 Portfolio Assessment 8.14.3 SWOT Analysis 8.15 Peter Brehm GMBH 8.15.1 Overview 8.15.2 Portfolio Assessment 8.15.3 SWOT Analysis 8.16 Serf Dedienne Santé 8.16.1 Overview 8.16.2 Portfolio Assessment 8.16.3 SWOT Analysis 8.17 Smith & Nephew 8.17.1 Overview 8.17.2 Portfolio Assessment 8.17.3 SWOT Analysis 8.18 Stelkast 8.18.1 Overview 8.18.2 Portfolio Assessment 8.18.3 SWOT Analysis 8.19 Stryker 8.19.1 Overview 8.19.2 Portfolio Assessment 8.19.3 SWOT Analysis 8.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 8.20.1 Overview 8.20.2 Portfolio Assessment 8.20.3 SWOT Analysis 8.21 Tornier N.V. 8.21.1 Overview 8.21.2 Portfolio Assessment 8.21.3 SWOT Analysis 8.22 Wright Medical 8.22.1 Overview 8.22.2 Portfolio Assessment 8.22.3 SWOT Analysis
8.23 United Orthopedic Corporation 8.23.1 Overview 8.23.2 Portfolio Assessment 8.23.3 SWOT Analysis 8.24 Zimmer Holdings Inc. 8.24.1 Overview 8.24.2 Portfolio Assessment 8.24.3 SWOT Analysis 8.25 Other Companies 9 Market Drivers, Opportunities and Barriers 9.1 Market Drivers 9.1.1 Prevalence Rise 9.1.2 Expanding Indications 9.1.3 Availability and Lack of Long-Term Clinical Data 9.1.4 Fracture Incidence 9.1.5 Patient Demand and Awareness 9.2 Opportunities 9.2.1 Revision Surgery 9.2.2 Emerging Markets 9.2.3 Continued Materials Research 9.2.4 Corporate Promotions and Teaching Seminars 9.2.5 Advancement towards Cost Reduction 9.3 Market Barriers 9.3.1 Market Barriers 10 Country Outlooks & Forecasts 10.1 US Market Analysis 11 Appendix 11.1 Abbreviations 11.2 Bibliography 11.3 Report Methodology 11.3.1 Overview 11.3.2 Coverage 11.3.3 Secondary Research 11.3.4 Forecasting Methodology 11.3.5 Primary Research Key Opinion Leader Interviews 11.3.6 Expert Panel Validation 11.4 Physicians and Specialists Included in this Study 11.4.1 Dr. Alessandro Aprato 11.4.2 Dr. Fran Channa 11.4.3 Joseph Daniel FRCS MS (Orth) 11.4.4 Dr. Alejandro Gonzalez Della Valle 11.4.5 Dr. Moussa Hamadouche 11.4.6 Dr. Sheng-Li Huang and Xi-Jing He 11.4.7 Dr. Ayumi Kaneuji 11.4.8 Dr. Yuichi Mitani 11.4.9 Dr. Ning Lu 11.4.10 Dr. Deepak Saini 11.4.11 Dr. Lafayette Lage 11.4.12 Dr. Christoph Zilkens 11.5 About the Authors 11.5.1 Analysts 11.5.2 Global Head of Healthcare 11.6 About MediPoint 11.7 About Us 11.8 Disclaimer 1.1 List of Tables Table 1: Clinical Symptoms and Descriptions Table 2: Advantages and Disadvantages of Hip Resurfacing Table 3: Surgical Approaches Comparison Table 4: Direct and Indirect Costs of Arthritis Table 5: Bicontact Universal Hip System (B. Braun) Table 6: Clinical Studies Bicontact Universal Hip System (B. Braun)
Table 7: SWOT Bicontact Universal Hip System Table 8: Excia Hip Stem (B. Braun) Table 9: Clinical Studies Excia Hip Stem (B. Braun) Table 10: SWOT Excia Hip Stem Table 11: Metha Short Hip Stem (B. Braun) Table 12: Clinical Studies Metha Short Hip Stem (B. Braun) Table 13: SWOT Metha Short Hip Stem Table 14: TRJ Cementless Hip Endoprosthesis System (B. Braun) Table 15: SWOT TRJ Cementless Hip Endoprosthesis System Table 16: Plasmacup SC Acetabular Cup (B. Braun) Table 17: Balance Femoral Component (Biomet) Table 18: Clinical Studies Balance Femoral Component (Biomet) Table 19: SWOT Balance Femoral Component Table 20: Bi-Metric Femoral Components (Biomet) Table 21: Clinical Studies Bi-Metric Femoral Components (Biomet) Table 22: SWOT Bi-Metric Femoral Components Table 23: Bio-Moore II Hip System (Biomet) Table 24: Clinical Studies Bio-Moore II Hip System (Biomet) Table 25: SWOT Bio-Moore II Hip System Table 26: Generation 4 Polished Hip System (Biomet) Table 27: SWOT Generation 4 Polished Hip System Table 28: Integral Porous Primary Hip System (Biomet) Table 29: Clinical Studies Integral Porous Hip System (Biomet) Table 30: SWOT Integral Porous Hip System Femoral Components Table 31: Mallory Femoral Component (Biomet) Table 32: Clinical Studies Mallory Femoral Component (Biomet) Table 33: SWOT Mallory Femoral Component Table 34: Progressive Total Hip System (Biomet) Table 35: SWOT Progressive Total Hip System Table 36: Rx 90 Smooth Primary Femoral Component (Biomet) Table 37: SWOT Rx 90 Smooth Primary Femoral Component Table 38: Stanmore Hip System (Biomet) Table 39: Clinical Studies Stanmore Hip System (Biomet) Table 40: SWOT Stanmore Hip System Table 41: Taperloc and Balance Microplasty Hip Stems (Biomet) Table 42: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) Table 43: SWOT Taperloc and Balance Microplasty Hip Stems Table 44: Acetabular Systems (Biomet) Table 45: Bencox Stems (Corentec Co. Ltd) Table 46: Clinical Studies Bencox Stems (Corentec Co. Ltd) Table 47: SWOT Bencox Stems Table 48: Bencox Acetabular Systems (Corentec Co. Ltd.) Table 49: MetaFix (Corin) Table 50: SWOT MetaFix Table 51: MiniHip (Corin) Table 52: SWOT MiniHip Table 53: MRP-Titan (Corin) Table 54: SWOT MRP-Titan Table 55: TaperFit (Corin) Table 56: SWOT TaperFit Table 57: Trinity Acetabular System (Corin) Table 58: Cenator Acetabular Cup (Corin) Table 59: Cementless Systems (DePuy Synthes) Table 60: Clinical Studies Cementless Systems (DePuy Synthes) Table 61: SWOT DePuy Synthes Cementless Systems Table 62: Cemented Systems (DePuy Synthes) Table 63: Clinical Studies Cemented Systems (DePuy Synthes) Table 64: SWOT DePuy Synthes Cemented Systems Table 65: DePuy Synthes Acetabular Systems (DePuy Synthes) Table 66: AcuMatch Femoral Stems (Exactech) Table 67: Clinical Studies AcuMatch Femoral Stems (Exactech) Table 68: SWOT AcuMatch Femoral Stems Table 69: Novation Femoral Stems (Exactech)
Table 70: Clinical Studies Novation Femoral Stems (Exactech) Table 71: SWOT Novation Femoral Stems Table 72: Exactech Acetabular Systems (Exactech) Table 73: i-hip Total Hip Implant (Iconacy Orthopedic Implants) Table 74: SWOT i-hip Total Hip Implant Table 75: EcoFit Femoral Stem (Implantcast GMBH) Table 76: Aida Short Femoral Stem (Implantcast GMBH) Table 77: AJS Hip System (Implantcast GMBH) Table 78: DiaLoc Hip Stem (Implantcast GMBH) Table 79: LOAD SHIFT Hip Stem (Implantcast GMBH) Table 80: Ceraco Hip Stem (Implantcast GMBH) Table 81: IC Straight Stem Type I and Type II (Implantcast GMBH) Table 82: Bicana Hip Stem (Implantcast GMBH) Table 83: SWOT Implantcast GMBH Femoral Stems Table 84: Implantcast GMBH Acetabular Cups (Implantcast GMBH) Table 85: Aeon Hip System (JRI Orthopaedics) Table 86: SWOT Aeon Hip System Table 87: Furlong Hip System and Evolution System (JRI Orthopaedics) Table 88: Clinical Studies Furlong Hip System (JRI Orthopaedics) Table 89: SWOT Furlong Hip System and Evolution System Table 90: Limacorporate Cementless Femoral Stems (Limacorporate SPA) Table 91: SWOT Limacorporate Cementless Femoral Stems Table 92: Cemented and Cementless Stems (Limacorporate SPA) Table 93: SWOT Cemented and Cementless Stems (Limacorporate SPA) Table 94: Limacorporate Acetabular Systems Table 95: Cemented and Cementless Stems (Medacta) Table 96: SWOT Medacta Stems Table 97: Acetabular Cups and Femoral Heads (Medacta) Table 98: Helicon Hip System (TGM Medical, wholly owned by Medtronic) Table 99: SWOT Helicon Hip System Table 100: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) Table 101: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) Table 102: SWOT Peter Brehm Products Table 103: Libra and Sagittal EVL (Serf Dedienne Santé) Table 104: SWOT Libra and Sagittal EVL Table 105: Acetabular Cups (Serf Dedienne Santé) Table 106: Echelon and Synergy (Smith & Nephew) Table 107: SWOT Echelon and Synergy Table 108: Anthology Hip System (Smith & Nephew) Table 109: SWOT Anthology Hip System Table 110: CPCS and Spectron Hip System (Smith & Nephew) Table 111: SWOT CPCS and Spectron Hip System Table 112: Emperion and SMF Modular Stems (Smith & Nephew) Table 113: SWOT Emperion and SMF Modular Stems Table 114: Acetabular Cups (Smith & Nephew) Table 115: ProClass Hip Stem (Stelkast) Table 116: SWOT ProClass Hip Stem Table 117: Progeny Hip Stem (Stelkast) Table 118: SWOT Progeny Hip Stem Table 119: Protract Hip Stem (Stelkast) Table 120: SWOT Protract Hip Stem Table 121: Provident Hip Stem (Stelkast) Table 122: SWOT Provident Hip Stem Table 123: Acetabular Cups (Stelkast) Table 124: Cementless Stems (Stryker) Table 125: SWOT Cementless Stems Table 126: Cemented Stems (Stryker) Table 127: SWOT Cemented Stems Table 128: Acetabular Systems (Stryker) Table 129: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) Table 130: SWOT Diamond Total Hip Implant Table 131: Linea Stem (Tornier N.V.) Table 132: SWOT Linea Stem
Table 133: Meije Duo Stem (Tornier N.V.) Table 134: SWOT Meije Duo Stem Table 135: Oceane Stem (Tornier N.V.) Table 136: SWOT Oceane Stem Table 137: Tornier Femoral Heads (Tornier N.V.) Table 138: Oceane Cup (Tornier N.V.) Table 139: Tornier Dynacup (Tornier N.V.) Table 140: Tornier Dual Mobility (Tornier N.V.) Table 141: Perfecta Cementless and Cemented Stems (Wright Medical) Table 142: SWOT Perfecta Cementless and Cemented Stems Table 143: Cementless Femoral Stems (Wright Medical) Table 144: SWOT Cementless Femoral Stems Table 145: Cemented Femoral Stems (Wright Medical) Table 146: SWOT Cemented and Cementless Femoral Stems (Wright Medical) Table 147: Acetabular Systems (Wright Medical) Table 148: UTF and UTF Reduced Stem (United Orthopedic Company) Table 149: SWOT UTF and UTF Reduced Stem Table 150: Hip U1 and U2 Stems (United Orthopedic Corporation) Table 151: SWOT Acetabular Systems (United Orthopedic Corporation) Table 152: Acetabular Systems (United Orthopedic Corporation) Table 153: Press-Fit Stems (Zimmer Holdings Inc.) Table 154: SWOT Press-Fit Stems Table 155: Acetabular Systems (Zimmer Holdings Inc.) Table 156: Exactech LPI Prime Hip System (Exactech) Table 157: Company Profile B. Braun Table 158: B. Braun Product Portfolio Table 159: SWOT Analysis B. Braun Table 160: Company Profile Biomet Orthopedics Table 161: Biomet Product Portfolio Table 162: SWOT Analysis Biomet Orthopedics Table 163: Company Profile Corentec Co. Ltd. Table 164: Corentec Product Portfolio Table 165: SWOT Analysis Corentec Co. Ltd. Table 166: Company Profile Corin Group Table 167: Corin Group Product Portfolio Table 168: SWOT Analysis Corin Group Table 169: Company Profile DePuy Synthes International Table 170: DePuy Synthes International Product Portfolio Table 171: SWOT Analysis DePuy Synthes International Table 172: Company Profile Exactech Table 173: Exactech Product Portfolio Table 174: SWOT Analysis Exactech Table 175: Company Profile Iconacy Orthopedic Implants LLC Table 176: Iconacy Orthopedic Implants LLC Product Portfolio Table 177: SWOT Analysis Iconacy Orthopedic Implants LLC Table 178: Company Profile Implantcast GMBH Table 179: Implantcast GMBH Product Portfolio Table 180: SWOT Analysis Implantcast GMBH Table 181: Company Profile JRI Orthopaedics Table 182: JRI Orthopaedics Product Portfolio Table 183: SWOT Analysis JRI Orthopaedics Table 184: Company Profile KYOCERA Medical Corporation Table 185: KYOCERA Medical Corporation Product Portfolio Table 186: SWOT Analysis KYOCERA Medical Corporation Table 187: Company Profile Limacorporate S.P.A Table 188: Limacorporate S.P.A Product Portfolio Table 189: SWOT Analysis Limacorporate S.P.A Table 190: Company Profile Medacta International Table 191: Medacta International Product Portfolio Table 192: SWOT Analysis Medacta International Table 193: Company Profile Medtronic Table 194: Medtronic Product Portfolio Table 195: SWOT Analysis Medtronic
Table 196: Company Profile NovoSource Inc. Table 197: NovoSource Inc. Product Portfolio Table 198: SWOT Analysis NovoSource Inc. Table 199: Company Profile Peter Brehm GMBH Table 200: Peter Brehm GMBH Product Portfolio Table 201: SWOT Analysis Peter Brehm GMBH Table 202: Company Profile Serf Dedienne Santé Table 203: Serf Dedienne Santé Product Portfolio Table 204: SWOT Analysis Serf Dedienne Santé Table 205: Company Profile Smith & Nephew Table 206: Smith & Nephew Product Portfolio Table 207: SWOT Analysis Smith & Nephew Table 208: Company Profile Stelkast Table 209: Stelkast Product Portfolio Table 210: SWOT Analysis Stelkast Table 211: Company Profile Stryker Table 212: Stryker Product Portfolio Table 213: SWOT Analysis Stryker Table 214: Company Profile Tianjin Zhengtian Medical Instrument Co. Ltd. Table 215: Tianjin Zhengtian Medical Instrument Co. Ltd. Product Portfolio Table 216: SWOT Analysis Tianjin Zhengtian Medical Instrument Co. Ltd. Table 217: Company Profile Tornier N.V. Table 218: Tornier N.V. Product Portfolio Table 219: SWOT Analysis Tornier N.V. Table 220: Company Profile Wright Medical Table 221: Wright Medical Product Portfolio Table 222: SWOT Analysis Wright Medical Table 223: Company Profile United Orthopedic Corporation Table 224: United Orthopedic Corporation Product Portfolio Table 225: SWOT Analysis United Orthopedic Corporation Table 226: Company Profile Zimmer Holdings Inc. Table 227: Zimmer Holdings Inc. Product Portfolio Table 228: SWOT Analysis Zimmer Holdings, Inc. Table 229: Other Companies in the Global Hip Replacement Market Table 230: US Sales ($m) Forecast for THR, 2010 2019 1.2 List of Figures Figure 1: Anatomy of the Hip Figure 2: Treatment Paradigm for Hip Osteoarthritis Figure 3: Treatment Paradigm for Hip Fractures Figure 4: Hip Arthrodesis Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally Figure 7: Surgical Approach Used by Orthopedic Surgeons in North America Figure 8: Population with Osteoarthritis in the US, 2010 2019 Figure 9: Costs Related to Total Hip Replacement Figure 10: Global Market Share for Reconstructive Products, 2012 Figure 11: US Market Share for Hip Replacement Products, 2010 Figure 12: Bicontact Universal Hip System (B. Braun) Figure 13: Excia Hip Stem (B. Braun) Figure 14: Metha Short Hip Stem (B. Braun) Figure 15: TRJ Cementless Hip Endoprosthesis System (B. Braun) Figure 16: Plasmacup SC Acetabular Cup (B. Braun) Figure 17: Balance Femoral Component (Biomet) Figure 18: Bi-Metric Femoral Components (Biomet) Figure 19: Bio-Moore II Hip System (Biomet) Figure 20: Generation 4 Polished Hip System (Biomet) Figure 21: Integral Porous Primary Hip System (Biomet) Figure 22: Mallory Femoral Component (Biomet) Figure 23: Progressive Total Hip System (Biomet) Figure 24: Rx 90 Smooth Primary Femoral Component (Biomet) Figure 25: Stanmore Hip System (Biomet) Figure 26: Taperloc and Balance Microplasty Hip Stems (Biomet)
Figure 27: Bencox Stems (Corentec Co. Ltd) Figure 28: Bencox Acetabular Systems (Corentec Co. Ltd.) Figure 29: MetaFix (Corin) Figure 30: MiniHip (Corin) Figure 31: MRP-Titan (Corin) Figure 32: TaperFit (Corin) Figure 33: Trinity Acetabular System (Corin) Figure 34: Cenator Acetabular Cup (Corin) Figure 35: Cementless Systems (DePuy Synthes) Figure 36: Cemented Systems (DePuy Synthes) Figure 37: DePuy Acetabular Systems (DePuy Synthes) Figure 38: AcuMatch Femoral Stems (Exactech) Figure 39: Novation Femoral Stems (Exactech) Figure 40: i-hip Total Hip Implant (Iconacy Orthopedic Implants) Figure 41: EcoFit Femoral Stem (Implantcast GMBH) Figure 42: Aida Short Femoral Stem (Implantcast GMBH) Figure 43: AJS Hip System (Implantcast GMBH) Figure 44: DiaLoc Hip Stem (Implantcast GMBH) Figure 45: LOAD SHIFT Hip Stem (Implantcast GMBH) Figure 46: Ceraco Hip Stem (Implantcast GMBH) Figure 47: IC Straight Stem Type I and Type II (Implantcast GMBH) Figure 48: Bicana Hip Stem (Implantcast GMBH) Figure 49: Implantcast GMBH Acetabular Cups (Implantcast GMBH) Figure 50: Aeon Hip System (JRI Orthopaedics) Figure 51: Furlong Hip System and Evolution System (JRI Orthopaedics) Figure 52: Cemented and Cementless Stems (Limacorporate SPA) Figure 53: Cemented and Cementless Stems (Medacta) Figure 54: Helicon Hip System (TGM Medical wholly owned by Medtronic) Figure 55: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) Figure 56: Libra and Sagitta EVL (Serf Dedienne Santé) Figure 57: Acetabular Cups (Serf Dedienne Santé) Figure 58: Echelon and Synergy (Smith & Nephew) Figure 59: Anthology Hip System (Smith & Nephew) Figure 60: CPCS and Spectron Hip System (Smith & Nephew) Figure 61: Emperion and SMF Modular Stems (Smith & Nephew) Figure 62: Acetabular Cups (Smith & Nephew) Figure 63: ProClass Hip Stem (Stelkast) Figure 64: Progeny Hip Stem (Stelkast) Figure 65: Protract Hip Stem (Stelkast) Figure 66: Provident Hip Stem (Stelkast) Figure 67: Acetabular Systems (Stelkast) Figure 68: Cementless Stems (Stryker) Figure 69: Cemented Stems (Stryker) Figure 70: Acetabular Systems (Stryker) Figure 71: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) Figure 72: Linea Stem (Tornier N.V.) Figure 73: Meije Duo Stem (Tornier N.V.) Figure 74: Oceane Stem (Tornier N.V.) Figure 75: Tornier Femoral Heads (Tornier N.V.) Figure 76: Oceane Cup (Tornier N.V.) Figure 77: Tornier Dynacup (Tornier N.V.) Figure 78: Tornier Dual Mobility (Tornier N.V.) Figure 79: Perfecta Cementless and Cemented Stems (Wright Medical) Figure 80: Cementless Femoral Stems (Wright Medical) Figure 81: Profemur Gladiator (Wright Medical) Figure 82: Acetabular Systems (Wright Medical) Figure 83: UTF and UTF Reduced Stem (United Orthopedic Corporation) Figure 84: Hip U1 and U2 Stems (United Orthopedic Corporation) Figure 85: Acetabular Systems (United Orthopedic Corporation) Figure 86: Press-Fit Stems (Zimmer Holdings Inc.) Figure 87: Acetabular Systems (Zimmer Holdings Inc.) Figure 88: US Primary Hip Arthroplasty Procedure Volumes (2010 2019) Figure 89: Arthroplasty Cost Breakdown With Patient Discharged Home (2007)
Figure 90: Medicare Payment Trend for Hip and Knee Joint Replacement, 1985 2009 Figure 91: US Sales ($m) Forecast for THR, 2010 2019 Ordering: Order Online - http://www.researchandmarkets.com/reports/2629674/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: MediPoint: Total Hip Replacement - US Analysis and Market Forecasts http://www.researchandmarkets.com/reports/2629674/ SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 4450 USD 8900 USD 11645 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World